NCT02650635View on ClinicalTrials.gov

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 5, 2016

Primary Completion Date

September 26, 2016

Study Completion Date

June 1, 2017

Conditions
Colorectal AdenocarcinomaMetastatic Pancreatic AdenocarcinomaRecurrent Breast CarcinomaRecurrent Colorectal CarcinomaRecurrent Melanoma of the SkinRecurrent Non-Small Cell Lung CarcinomaRecurrent Pancreatic CarcinomaRecurrent Renal Cell CarcinomaSolid NeoplasmStage IV Breast CancerStage IV Non-Small Cell Lung CancerStage IV Renal Cell CancerStage IV Skin MelanomaStage IVA Colorectal CancerStage IVA Pancreatic CancerStage IVB Colorectal CancerStage IVB Pancreatic Cancer
Interventions
DRUG

Cyclophosphamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pegfilgrastim

Given SC

OTHER

Pharmacological Study

Correlative studies

DRUG

TLR8 Agonist VTX-2337

Given SC

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER